This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gnant, M. F. X. Articles by Bartlett, D. L. Search for Related Content PubMed PubMed Citation Articles by Gnant, M. F. X. Articles by Bartlett, D. L.

Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Gene and Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gene Expression and Prolongation of Survival in Mice¹

Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 [M. F. X. G., M. P., H. R. A., D. L. B.]; Department of Surgery, University of Vienna, A-1090 Vienna, Austria [M. F. X. G.]; and Department of Surgery, Technical University Munich, D-81675 Munich, Germany [M. P.]

Suicide gene therapy using the cytosine deaminase (CD) gene and 5-fluorocytosine (5-FC) has shown promising results for the treatment of colon carcinoma cells in vitro. Efficient viral infection and tumor-specific gene delivery is crucial for clinically measurable treatment effects. After proving efficient gene transfer in vitro, we demonstrate here that genes can be delivered to metastatic liver tumors in vivo in a highly selective manner using systemic delivery of a thymidine kinase-deleted (TK-) recombinant vaccinia virus (Western Reserve strain). When the vector was administered systemically in C57BL/6 mice or nude/athymic mice with established disseminated MC38 liver metastases, transgene expression in tumors was usually 1,000- to 10,000-fold higher compared with other organs (n = 160; P < 0.00001). This tumor-specific gene transfer leads to significant tumor responses and subsequent survival benefits after the transfer of the CD gene to liver metastases and subsequent systemic treatment with the prodrug 5-FC (P < 0.0001). We describe reporter gene and survival experiments both in immunocompetent and athymic nude mice, establishing a gene expression pattern over time and characterizing the treatment effects of the virus delivery/prodrug system. Cure rates of up to 30% in animals with established liver metastases show that suicide gene therapy using TK- vaccinia virus as a vector may be a promising system for the clinical application of tumor-directed gene therapy.

This article has been cited by other articles:

				H. S. Kim, S. Kim-Schulze, D. W. Kim, and H. L. Kaufman Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand Cancer Res., November 1, 2009; 69(21): 8516 - 8525. [Abstract] [Full Text] [PDF]

				A. Frentzen, Y. A. Yu, N. Chen, Q. Zhang, S. Weibel, V. Raab, and A. A. Szalay Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy PNAS, August 4, 2009; 106(31): 12915 - 12920. [Abstract] [Full Text] [PDF]

				K. Hiraoka, T. Kimura, C. R. Logg, C.-K. Tai, K. Haga, G. W. Lawson, and N. Kasahara Therapeutic Efficacy of Replication-Competent Retrovirus Vector-Mediated Suicide Gene Therapy in a Multifocal Colorectal Cancer Metastasis Model Cancer Res., June 1, 2007; 67(11): 5345 - 5353. [Abstract] [Full Text] [PDF]

				Z. S. Guo, A. Naik, M. E. O'Malley, P. Popovic, R. Demarco, Y. Hu, X. Yin, S. Yang, H. J. Zeh, B. Moss, et al. The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2 Cancer Res., November 1, 2005; 65(21): 9991 - 9998. [Abstract] [Full Text] [PDF]

				J. W. Hodge, D. J. Poole, W. M. Aarts, A. Gomez Yafal, L. Gritz, and J. Schlom Modified Vaccinia Virus Ankara Recombinants Are as Potent as Vaccinia Recombinants in Diversified Prime and Boost Vaccine Regimens to Elicit Therapeutic Antitumor Responses Cancer Res., November 15, 2003; 63(22): 7942 - 7949. [Abstract] [Full Text] [PDF]

				J. W. Hodge, D. W. Grosenbach, W. M. Aarts, D. J. Poole, and J. Schlom Vaccine Therapy of Established Tumors in the Absence of Autoimmunity Clin. Cancer Res., May 1, 2003; 9(5): 1837 - 1849. [Abstract] [Full Text] [PDF]

				J. A. McCart, J. M. Ward, J. Lee, Y. Hu, H. R. Alexander, S. K. Libutti, B. Moss, and D. L. Bartlett Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes Cancer Res., December 1, 2001; 61(24): 8751 - 8757. [Abstract] [Full Text] [PDF]

				Y. Hu, J. Lee, J. A. McCart, H. Xu, B. Moss, H. R. Alexander, and D. L. Bartlett Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy J. Virol., November 1, 2001; 75(21): 10300 - 10308. [Abstract] [Full Text] [PDF]

				D. W. Grosenbach, J. C. Barrientos, J. Schlom, and J. W. Hodge Synergy of Vaccine Strategies to Amplify Antigen-specific Immune Responses and Antitumor Effects Cancer Res., June 1, 2001; 61(11): 4497 - 4505. [Abstract] [Full Text] [PDF]

				V. Pierrefite-Carle, A. Gavelli, N. Brossette, P. Baque, D. Benchimol, A. Bourgeon, P. Staccini, and B. Rossi Re: Cytosine Deaminase/5-Fluorocytosine-Based Vaccination Against Liver Tumors: Evidence of Distant Bystander Effect J Natl Cancer Inst, March 15, 2000; 92(6): 494 - 495. [Full Text] [PDF]

				M. F. X. Gnant, L. A. Noll, K. R. Irvine, M. Puhlmann, R. E. Terrill, H. R. Alexander Jr., and D. L. Bartlett Tumor-Specific Gene Delivery Using Recombinant Vaccinia Virus in a Rabbit Model of Liver Metastases J Natl Cancer Inst, October 20, 1999; 91(20): 1744 - 1750. [Abstract] [Full Text] [PDF]